Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879

• Published in: Investigational new drugs Vol. 39; no. 3; pp. 812 - 820
• Main Authors: Quinn, David I., Tsao-Wei, Denice D., Twardowski, Przemyslaw, Aparicio, Ana M., Frankel, Paul, Chatta, Gurkamal, Wright, John J., Groshen, Susan G., Khoo, Stella, Lenz, Heinz-Josef, Lara, Primo N., Gandara, David R., Newman, Edward
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2021; Springer Nature B.V
• Subjects: Adult; Aged; Aged, 80 and over; Anticancer properties; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antitumor activity; Apoptosis; Bladder; Bladder cancer; Cancer; Carcinoma, Transitional Cell - drug therapy; Carcinoma, Transitional Cell - mortality; Carcinoma, Transitional Cell - pathology; Computed tomography; Consortia; Cytopenia; Dosage; Female; Histone deacetylase; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - adverse effects; Histones; Humans; Hydroxamic acid; Inhibitors; Kaplan-Meier Estimate; Lymphocytes; Lymphocytes T; Magnetic resonance imaging; Male; Medical imaging; Medicine; Medicine & Public Health; Metastases; Metastasis; Middle Aged; Neoplasm Recurrence, Local - drug therapy; Neoplasm Recurrence, Local - mortality; Neoplasm Recurrence, Local - pathology; Oncology; Pharmacology/Toxicology; Phase II Studies; Platinum; Schedules; Survival; Therapy; Toxicity; Transitional cell carcinoma; Treatment Outcome; Tumor cell lines; Urologic Neoplasms - drug therapy; Urologic Neoplasms - mortality; Urologic Neoplasms - pathology; Urothelial cancer; Urothelium; Urothelium - pathology; Vorinostat - administration & dosage; Vorinostat - adverse effects; Urothelial cancer; Clinical trial; Histone deacetylase inhibitor; Bladder cancer

Summary Background: Until the advent of T cell check point inhibitors standard second-line therapy for patients with metastatic urothelial cancer (mUC) was undefined. Histone deacetylase inhibitors (HDACi) have anti-cancer activity in a variety of tumor models including modulation of apoptosis in bl...